

**To:** Waleko, Garland[waleko.garland@epa.gov]  
**From:** Guilaran, Yu-Ting  
**Sent:** Tue 5/23/2017 11:13:27 AM  
**Subject:** FW: Acute dermal HSUS response

Please see Kelly's response below. Can you check with EFED about the BE schedule?

Regards,

Yu-Ting Guilaran, P.E.

Director

Pesticide Re-evaluation Division (PRD)

Office of Pesticide Programs

Office of Chemical Safety and Pollution Prevention

(tel) 703 308 0052

(fax)703 308 8005

Mail code 7508P

Room number PY S9623

**From:** Sherman, Kelly  
**Sent:** Monday, May 22, 2017 5:18 PM  
**To:** Guilaran, Yu-Ting <Guilaran.Yu-Ting@epa.gov>; Costello, Kevin <Costello.Kevin@epa.gov>; Smith, Charles <Smith.Charles@epa.gov>  
**Subject:** RE: Acute dermal HSUS response

A couple of thoughts. Spring is almost over.

The FRN is drafted (and maybe signed?) but it is caught with the other FRNs.

## Ex. 5 - Deliberative Process

Kelly Sherman

Chief, Risk Management and Implementation Branch III (RMIB III)

Pesticide Re-Evaluation Division

Office of Pesticide Programs

U.S. Environmental Protection Agency

(703) 305-8401

**From:** Guilaran, Yu-Ting

**Sent:** Monday, May 22, 2017 5:08 PM

**To:** Sherman, Kelly <[Sherman.Kelly@epa.gov](mailto:Sherman.Kelly@epa.gov)>; Costello, Kevin <[Costello.Kevin@epa.gov](mailto:Costello.Kevin@epa.gov)>;  
Smith, Charles <[Smith.Charles@epa.gov](mailto:Smith.Charles@epa.gov)>

**Subject:** Fwd: Acute dermal HSUS response

Kevin and Kelly

Can you confirm that we are good w the highlighted language below?

Sent from my iPhone

Begin forwarded message:

**From:** "Waleko, Garland" <[Waleko.Garland@epa.gov](mailto:Waleko.Garland@epa.gov)>

**Date:** May 22, 2017 at 3:37:43 PM EDT

**To:** "Guilaran, Yu-Ting" <[Guilaran.Yu-Ting@epa.gov](mailto:Guilaran.Yu-Ting@epa.gov)>  
**Cc:** "Lowit, Anna" <[Lowit.Anna@epa.gov](mailto:Lowit.Anna@epa.gov)>  
**Subject:** RE: Acute dermal HSUS response

Hi Yu-Ting, I just wanted to check in on this response to the humane society, because we mention the methomyl/carbaryl BE's

Garland

**From:** Waleko, Garland  
**Sent:** Tuesday, May 02, 2017 8:50 AM  
**To:** Guilaran, Yu-Ting <[Guilaran.Yu-Ting@epa.gov](mailto:Guilaran.Yu-Ting@epa.gov)>  
**Cc:** Lowit, Anna <[Lowit.Anna@epa.gov](mailto:Lowit.Anna@epa.gov)>  
**Subject:** FW: Acute dermal HSUS response

Good morning Yu-Ting,

FEAD suggested that I run this Humane Society response by you, because it includes a mention of the methomyl and carbaryl BE's, see highlight below. We developed this answer back in early January, and we may need to re-word.

Please let me know your thoughts when you get a chance.

Thanks,

Garland

**From:** Waleko, Garland  
**Sent:** Tuesday, April 25, 2017 4:30 PM  
**To:** Overstreet, Anne <[overstreet.anne@epa.gov](mailto:overstreet.anne@epa.gov)>  
**Cc:** Lowit, Anna <[Lowit.Anna@epa.gov](mailto:Lowit.Anna@epa.gov)>  
**Subject:** Acute dermal HSUS response

Hi Anne - as follow up to a call we had with the HSUS earlier this year, we are now getting back to them on the EFED specific questions. The first answer was developed with/approved by Ed Odenkirchen. The second was provided by Anita. Just wanted to run this by you quickly before sending on to HSUS.

Thanks!

Garland

Good afternoon Kate,

Apologies for the delay in getting you this response, below.

Q: It was interesting to hear from EFED that they don't actually use dermal acute data in their assessments. Would this allow OPP to reconsider whether they would accept oral to dermal acute bridging for ingredients as well as formulations as the preponderance of data suggest possible?

## **Ex. 5 - Deliberative Process**

Q: We understand that EFED is in the process of revising their assessment procedures to align with recommendations from the 2013 NAS report; is there an opportunity to be involved in this process?

## **Ex. 5 - Deliberative Process**

# **Ex. 5 - Deliberative Process**

Best,

Garland